Revance Begins Injectable Trial

Revance Therapeutics, a biopharmaceutical company, has announced Phase 2 BELMONT trial. This randomized, double-blind, dose ranging, active, and placebo controlled, multicenter study will evaluate the safety and efficacy of RT002, a botulinum toxin type A injectable intended to treat glabellar lines. The RT002 has the potential to address additional therapeutic indications where more targeted delivery is required or a longer duration is desired, for example movement disorders, urology, and ophthalmology. There are 250 participants expected to enroll at up to 10 sites in Canada. “The opportunity for a longer-lasting, more targeted neurotoxin is tremendous as it offers the potential for improved patient satisfaction and safety with longer-lasting results,” says Dan Browne, cofounder, president, and CEO of Revance Therapeutics. “Based on the current progress of our program, we expect to report top-line date from this Phase 2 study in late 2015.”

Suggested Articles

Holly Cutler shares her expert thoughts on what to expect from medical spas in 2020.

Allergan Aesthetics will operate as a new business with its own research and development function under the AbbVie umbrella.

Keravive is designed to cleanse, stimulate, nourish, and hydrate the scalp for fuller and healthier-looking hair.